639 related articles for article (PubMed ID: 18829477)
1. The use of genomics in clinical trial design.
Simon R
Clin Cancer Res; 2008 Oct; 14(19):5984-93. PubMed ID: 18829477
[TBL] [Abstract][Full Text] [Related]
2. American Society of Clinical Oncology guidance statement: the cost of cancer care.
Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
[TBL] [Abstract][Full Text] [Related]
3. Translational research in oncology: key bottlenecks and new paradigms.
Simon R
Expert Rev Mol Med; 2010 Oct; 12():e32. PubMed ID: 20929594
[TBL] [Abstract][Full Text] [Related]
4. Clinical trials for predictive medicine.
Simon R
Stat Med; 2012 Nov; 31(25):3031-40. PubMed ID: 22714719
[TBL] [Abstract][Full Text] [Related]
5. Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction?
LoRusso PM; Anderson AB; Boerner SA; Averbuch SD
Clin Cancer Res; 2010 Dec; 16(24):5956-62. PubMed ID: 21169248
[TBL] [Abstract][Full Text] [Related]
6. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
7. Ethical challenges in cancer research in children.
Berg SL
Oncologist; 2007 Nov; 12(11):1336-43. PubMed ID: 18055854
[TBL] [Abstract][Full Text] [Related]
8. Future of clinical genomics in pediatric oncology.
Janeway KA; Place AE; Kieran MW; Harris MH
J Clin Oncol; 2013 May; 31(15):1893-903. PubMed ID: 23589558
[TBL] [Abstract][Full Text] [Related]
9. [Genomics and clinical research for breast cancer].
Bertucci F; Birnbaum D
Med Sci (Paris); 2012 Mar; 28 Spec No 1():14-8. PubMed ID: 22494651
[TBL] [Abstract][Full Text] [Related]
10. End points in cancer clinical trials and the drug approval process.
Schilsky RL
Clin Cancer Res; 2002 Apr; 8(4):935-8. PubMed ID: 11948095
[TBL] [Abstract][Full Text] [Related]
11. Beyond genomics.
Dollery CT
Clin Pharmacol Ther; 2007 Oct; 82(4):366-70. PubMed ID: 17851575
[TBL] [Abstract][Full Text] [Related]
12. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
Takimoto CH
Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
[TBL] [Abstract][Full Text] [Related]
13. Designing transformative clinical trials in the cancer genome era.
Sleijfer S; Bogaerts J; Siu LL
J Clin Oncol; 2013 May; 31(15):1834-41. PubMed ID: 23589555
[TBL] [Abstract][Full Text] [Related]
14. Clinical trial designs for predictive marker validation in cancer treatment trials.
Sargent DJ; Conley BA; Allegra C; Collette L
J Clin Oncol; 2005 Mar; 23(9):2020-7. PubMed ID: 15774793
[TBL] [Abstract][Full Text] [Related]
15. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
16. Structural genomics in the biotechnology sector.
Dry S; McCarthy S; Harris T
Nat Struct Biol; 2000 Nov; 7 Suppl():946-9. PubMed ID: 11103995
[TBL] [Abstract][Full Text] [Related]
17. [Human genome sequencing--next generation technology or will the routine sequencing of human genome be possible?].
Pospísilová S; Tichý B; Mayer J
Cas Lek Cesk; 2009; 148(7):296-302. PubMed ID: 19642294
[TBL] [Abstract][Full Text] [Related]
18. The end of the beginning for genomic medicine.
Bailey D; Zanders E; Dean P
Nat Biotechnol; 2001 Mar; 19(3):207-9. PubMed ID: 11231543
[No Abstract] [Full Text] [Related]
19. Implications of pharmacogenomics for drug development.
Kirk RJ; Hung JL; Horner SR; Perez JT
Exp Biol Med (Maywood); 2008 Dec; 233(12):1484-97. PubMed ID: 18849536
[TBL] [Abstract][Full Text] [Related]
20. On the efficiency of targeted clinical trials.
Maitournam A; Simon R
Stat Med; 2005 Feb; 24(3):329-39. PubMed ID: 15551403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
